Hemophilia A is an inherited bleeding disorder caused by factor VIII (FVIII) deficiency. In most minor-to-moderate bleeding events, FVIII concentrates therapy can result in significant lifesaving. However, chronic FVIII concentrates therapy can cause FVIII inhibitors synthesis and replacement therapy inefficacious. Immunosuppressive therapy can suppress FVIII inhibitors synthesis and make FVIII concentrates therapy more responsive. This study aims to determine the effects of low-dose methylprednisolone on acquired FVIII inhibitors. A randomized clinical trial was conducted on 11 hemophilia A male patients with high level of FVIII inhibitors. This pretest-posttest study design consists of intervention group (6 patients) who received 1 mg/bodyweight/day methylprednisolone, and control group (5 patients) received 100 mg/day sugar pill placebo for 6 weeks. Statistical analysis used independent t-test and paired t-test. Results showed significant FVIII inhibitors rising in pretest-posttest mean comparison of both intervention group (p = 0.001) and control group (p = 0.001). Further result showed inter-groups pretest mean comparison (p = 0.976) and inter-groups posttest mean comparison (p = 0.034). We conclude that low-dose methylprednisolone significantly suppresses the FVIII inhibitors synthesis pace within 6 weeks instead of inhibits the FVIII inhibitors synthesis.